Provided By GlobeNewswire
Last update: Sep 23, 2024
Châtillon, France, September 23, 2024
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that patient screening is complete for the Phase 3 trial, VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy), using the modified Viaskin Peanut Patch in children ages 4 – 7 years old with peanut allergy.
Read more at globenewswire.com